home/conference/asco-annual-meeting Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors Sabrina Serani July 20th 2024 Juneko Grilley-Olson, MD, discussed findings from a phase 2 study investigating the addition of immunotherapy to chemotherapy for the treatment of advanced angios...
The Annual Meeting of the American Society of Clinical Oncology (ASCO) was held from May 31 to June 4, 2024, in Chicago, IL. This event serves as a pivotal gathering for healthcare professionals committed to enhancing patient care and outcomes within the field of oncology....
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting grandly opened on May 31st, local time, in Chicago, USA. As the most influential international event in the field of oncology, this year's conference gathered top global oncology pharmaceutical companies, related enterprises, and...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting took place in Chicago, Illinois, from M...
8.Oh DY, et al. Three-year survival and safety update from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer. Cholangiocarcinoma Foundation 2024 Annual Conference. 9.Shroff RT, et al....
ASCO-2024年美国临床肿瘤学会年会官网https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 31 to June 4 in...
home/conference/asco-hematology Glofitamab Shows Benefit Regardless of Prior BTK Exposure in R/R MCL Tycel Phillips, MD July 3rd 2024 All patient populations benefitted from glofitamab in a phase 1/2 trial, but the design excluded capture of high-risk features present in similar studies. ...
Research presented at the annual meeting of the American Society of Clinical Oncology (ASCO) has the potential to change practice — and assumptions — about acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and blood cancer as a whole, according to the chief science officer of ...
International Association for the Study of Lung Cancer (IASLC) Chair, 2005 World Conference on Lung Cancer European Society for Medical Oncology (ESMO) Member, Scientific Program Sub-Committee (NSCLC, metastatic)for ESMO Annual Congress European Organization for Research and Treatment of Cancer (EORTC...